

positively associated with depressive patients (respective  $p=0.002$ ,  $p<0.001$ ,  $p=0.025$ ,  $p=0.001$  and  $p=0.003$ ) while stigma resistance was negatively correlated with depression ( $p<0.001$ ).

**Conclusions:** Our results confirmed that internalized stigma is associated with impaired QoL and depression in stabilized patients with schizophrenia-spectrum diagnosis.

**Keywords:** internal stigma; schizophrenia; Depression; quality of life

## EPP1161

### Mothers with schizophrenia: Treatment, quality of life and motherhood experience

S. Pérez Sánchez<sup>1\*</sup>, I. Martín Herrero<sup>1</sup>, M.A. Cutillas Fernández<sup>1</sup>, A. Crespo Portero<sup>2</sup> and D. Raya Güimil<sup>1</sup>

<sup>1</sup>Servicio De Psiquiatría, Servicio Murciano de Salud, Murcia, Spain

and <sup>2</sup>Servicio De Psiquiatría, Servicio Murciano de Salud, Lorca, Murcia, Spain

\*Corresponding author.

doi: 10.1192/j.eurpsy.2021.1375

**Introduction:** Schizophrenia is a chronic disease that deteriorates the functionality of patients, especially when forming a family and taking care of children. We are interested in analyzing the characteristics of mothers with schizophrenia and their degree of global activity when going from oral treatments to injectable treatments.

**Objectives:** 1 To assess the quality of life and functional level of mothers with schizophrenia receiving paliperidone treatment. 2. Compare quality of life and functional level when going from oral treatment to long-term injectables.

**Methods:** Sample: Mothers, 37-45 years old, diagnosed with schizophrenia in monotherapy with oral paliperidone who started treatment with Paliperidone Palmitate LD IM (200 - 300 mg / month). Retrospective data collection. QLS quality of life scale.

**Results:** 5 patients were included, caregivers of 1 child (80%), 2 children (20%) who met the inclusion criteria and completed the questionnaires. After its application and correction through non-parametric tests ( $N<30$ ). During oral treatment, scores were observed in the QLS questionnaire of: mean intrapsychic functions 34.2, mean interpersonal relationships 19, mean instrumental role 8, mean daily activities 8. After 12 weeks of treatment with Paliperidone Palmitate IM, scores were obtained: functions Medium intrapsychic 36, medium interpersonal relationships 23, medium instrumental role 15, medium daily activities 11. A better functioning of the patients was observed in the instrumental and daily activities categories.

**Conclusions:** In our experience, injectable long-acting Paliperidone Palmitate is associated with the perception of better quality of life in mothers with schizophrenia and increases the ease of administration as well as planning in their daily life.

**Keywords:** Schizophrenia; mother; paliperidone palmitate; quality of life.

## EPP1162

### Sexual dysfunction in adolescents with antipsychotics. evaluation and suitability of the treatment.

S. Pérez Sánchez\*, I. Martín Herrero, M.A. Cutillas Fernández, D. Raya Güimil and A. Crespo Portero

Servicio De Psiquiatría, Servicio Murciano de Salud, Murcia, Spain

\*Corresponding author.

doi: 10.1192/j.eurpsy.2021.1376

**Introduction:** Problems in sexual function associated with psychotropic drugs in adolescents with psychotic disorders are common in clinical practice. However, they are usually not taken into account in follow-up and are rarely reported by patients.

**Objectives:** 1. To analyze if there is sexual dysfunction in adolescents with antipsychotic treatment. 2. To assess the degree of sexual dysfunction.

**Methods:** Descriptive study in psychiatric outpatient clinics involving 14 men (aged 16 to 19) with antipsychotic treatment. Record prospectively through interviews between 2 and 4 months from the start of treatment. Sexual function was evaluated with the questionnaire SALSEX Informed consent.

**Results:** Initially, no sexual dysfunction scores are obtained. At 4 months, records of sexual dysfunction were observed in 67% of the patients with less impact in those with aripiprazole as antipsychotic treatment, with a moderate intensity (mean score 8.2; SD 4.7). 33% of cases report the problem spontaneously. Breaking down the reasons for sexual dysfunction: 50% decrease in libido, 20% delay in ejaculation and 7% impotence. The global tolerance to sexual dysfunction was poor, 45% with ideas to abandon treatment.

**Conclusions:** In our experience, sexual dysfunction is one of the main causes that make young patients abandon treatment and even follow-up. For what we consider, it is very relevant to systematically evaluate and be able to quantify this vital aspect of our patients, which on many occasions is not addressed in the consultation. Likewise, it will be necessary in future studies to describe in detail the psychotropic drugs associated with sexual dysfunction for better management and dose adjustment.

**Keywords:** ADOLESCENTS; ANTIPSYCHOTICS; SEXUAL DYSFUNCTION; ARIPIPRAZOLE

## EPP1163

### The universe of brief psychosis

T. Coelho Rocha\*, J. Cunha, S. Torres and A. Lopes

Psychiatry And Mental Health Department, Centro Hospitalar Barreiro-Montijo, Barreiro, Portugal

\*Corresponding author.

doi: 10.1192/j.eurpsy.2021.1377

**Introduction:** Nowadays, 'Acute and transient psychotic disorders' in ICD-10 and 'Brief psychotic disorders' in DSM-5 are both classifications of the same clinical entity. Over the years, several concepts have been formulated to define the same syndrome.

**Objectives:** To explore the historical evolution of brief psychotic disorders and relate them to current nosologies.

**Methods:** Literature review, using the most relevant papers, with the keywords "brief psychosis", "bouffée délirante", "cycloid psychosis", "psychogenic psychosis", "atypical psychosis" and "holodysphrenia".

**Results:** Initially, in 1896, Kahlbaum coined the term 'dysphrenia', a group of severe form of psychosis that remitted without showing the typical sequence of disease states and without leaving a lasting alteration. Later, Kraepelin included this kind of disorder in manic depressive illness, which he first named as 'periodic delirium' and then as 'delirious mania'. Magnan, in the pre-Kraepelinian era, created the term 'bouffée délirante', a sudden onset of delusional ideas with rapid evolution and intense symptomatology with complete remission usually followed after a short time. Later on, Henry Ey grabbed this entity and renewed it, contrasting it to the defined concept of schizophrenia. Other psychiatric schools have proposed numerous designations: 'cycloid psychosis' by Kleist from the